Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy
© Kashiwagi et al; licensee BioMed Central Ltd. 2007
Received: 06 April 2007
Accepted: 15 July 2007
Published: 15 July 2007
Resistance to modern adjuvant treatment is in part due to the failure of programmed cell death. Therefore the molecules that execute the apoptotic program are potential targets for the development of anti-cancer therapeutics. The sigma-2 receptor has been found to be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the sigma-2 receptor were found to induce cancer cell apoptosis.
The sigma-2 receptor was expressed at high levels in both human and murine pancreas cancer cell lines, with minimal or limited expression in normal tissues, including: brain, kidney, liver, lung, pancreas and spleen. Micro-PET imaging was used to demonstrate that the sigma-2 receptor was preferentially expressed in tumor as opposed to normal tissues in pancreas tumor allograft-bearing mice. Two structurally distinct sigma-2 receptor ligands, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo. Sigma-2 receptor ligands induced apoptosis in a dose dependent fashion in all pancreatic cell lines tested. At the highest dose tested (10 μM), all sigma-2 receptor ligands induced 10–20% apoptosis in all pancreatic cancer cell lines tested (p < 0.05). In pancreas tumor allograft-bearing mice, a single bolus dose of WC26 caused approximately 50% apoptosis in the tumor compared to no appreciable apoptosis in tumor-bearing, vehicle-injected control animals (p < 0.0001). WC26 significantly slowed tumor growth after a 5 day treatment compared to vehicle-injected control animals (p < 0.0001) and blood chemistry panels suggested that there is minimal peripheral toxicity.
We demonstrate a novel therapeutic strategy that induces a significant increase in pancreas cancer cell death. This strategy highlights a new potential target for the treatment of pancreas cancer, which has little in the way of effective treatments.
Pancreas cancer is the fourth most common cause of cancer-related mortality in the United States. There has been little progress in the management of this disease and the annual mortality rate remains nearly identical to the annual incidence rate. There were an estimated 37,000 deaths attributable to this disease in the United States in 2006. The five-year survival for patients diagnosed with pancreas cancer is only 4%. Poor outcome is the result of difficulty in achieving early diagnosis and failure of modern treatments including surgery, radiation and chemotherapy. Normally, chemotherapy and radiation therapy for pancreatic cancer is palliative. For localized disease surgery remains the single most effective therapy, however even with complete surgical resection, the prognosis remains dismal and the majority of patients recur with systemic metastases. Therefore there is a critical need for an effective systemic therapy utilizing a new strategy.
Programmed cell death or apoptosis is an essential process in cell homeostasis and eukaryotic development[2, 3]. Recent studies have shown that failure of apoptosis is both central to the evolution of cancer and related to resistance toward modern adjuvant treatment such as chemo- or radiation therapies [4–6]. Therefore, there is considerable interest in targeting the molecular pathways of apoptosis as a component of cancer therapy.
We and others have recently reported that intracellular delivery of pro-apoptotic peptides can induce apoptosis in cancer cells in vitro and in animal models of adenocarcinomas in vivo [7–9]. For example, we have studied TAT-Bim a dual domain molecule comprised of an internalization motif (the polybasic region of HIV-1 TAT) and a biological effector domain (the BH3 domain of Bim) which leads to apoptosis. To demonstrate anti-tumor effectiveness in vivo, the peptides were injected intra-tumorally due to the non-specific cell permeation capacity of the TAT peptide. Direct intra-tumoral injection of the TAT-Bim compound effectively reduced tumor size and prolonged survival in animal models of pancreatic cancer. In order to translate these promising anti-cancer approaches into clinically viable therapies, cancer cell-specific targeting is required. The targeting strategy or domain can then be combined with biological effector domain to achieve cancer cell-specific death with preservation of normal tissues.
Several strategies have been developed to target delivery of therapy to tumors. (1) Physical targeting with either directed radiation or intratumoral injection. (2) Receptor-directed targeting with antibodies (for example, Herceptin, rituximab) or ligands (for example, TRAIL). (3) Prodrugs that are activated by enzymes active in the local milieu (for example, MMP-9). (4) Differences in metabolic needs (for example, Gleevec[16, 17]). Each of these approaches has inherent limitations, for example physical targeting has no ability to treat distant metastases and the antibody- or ligand-based targeting approaches are restricted to portions of the tumor that are accessible to macromolecules.
In this study we have begun to explore whether small molecules that selectively accumulate in cancer cells may provide yet another approach to targeted therapeutic delivery. A number of small molecules have been used in whole-body imaging studies and preferentially accumulate in tumors. One such class of small molecules is the family of sigma-2 receptor ligands.
The sigma-2 receptor has been characterized as a molecule that is highly expressed in rapidly proliferating cells and down-regulated when cells become quiescent. Sigma-2 receptor expression has been reported in various human cancer cells such as breast, brain, bladder, colon and melanoma; however, no studies have been reported on sigma-2 receptor expression in pancreas adenocarcinoma. Sigma-2 receptor-specific ligands have been found to induce apoptosis [19–22], raising the possibility that these ligands can act as sensitizers to standard chemotherapies.
Here we extend the body of evidence that the sigma-2 receptors are generic cancer markers by demonstrating that the sigma-2 receptor are over-expressed in pancreatic cancer cell lines in vitro and in Panc-02 tumor allografts established in C57Bl/6 mice in vivo. We further demonstrate that sigma-2 receptor ligands induce apoptosis in pancreatic cancer cells via a caspase-3 dependent pathway. And finally we show that systemic treatment with sigma 2 receptor-specific ligands slows the growth of established tumors in allograft murine models of pancreatic cancer without disrupting organ function.
Sigma-2 receptor expression in vitro and in vivo
Sigma-2 receptor ligand induces caspase-3/7 dependent cancer cell apoptosis
In vivo treatment with a sigma-2 receptor ligand causes tumor apoptosis with minimal effects on normal tissues
Sigma-2 receptor ligand therapy slows tumor growth and confers a survival advantage in vivo
We and others have shown that sigma 2 receptor-specific ligands such as WC26 have both diagnostic and therapeutic potential. Although the sigma 2 receptor has not been identified, some characterization has occurred. It is an approximately 20 kDa protein exclusively found in lipid rafts throughout membrane encapsulated cellular compartments, yet it has resisted sequencing efforts. Pharmacologic studies suggest that the sigma 2 ligand binding site is well conserved between rodents and primates, and we have demonstrated that sigma 2 receptor-specific ligands induce apoptosis in both mouse and human pancreas adenocarcinoma cell lines equally.
Apoptosis is a crucial mechanism for cellular homeostasis and failure of this mechanism is central to the development of cancer and associated with resistance toward adjuvant treatment such as chemo- or radiation therapies[5, 24]. Overexpression of anti-apoptotic proteins including Bcl-2 family members and AKT/PKB pathway agonists have been found in a variety of human cancers including pancreas, breast, prostate  and lung. As a result, there is considerable interest in targeting the intracellular apoptotic apparatus for cancer therapy.
Sigma-2 receptor ligands have recently been reported to induce apoptosis in several tumor cells in vitro [19–22]. Here we reported that sigma-2 receptor is highly expressed in human and mouse pancreatic cancer cells, and sigma-2 receptor-selective ligands induce tumor apoptosis in a caspase-3 dependent manner. Mouse and human pancreatic cancer cell lines as well as established Panc-02 tumor allografts established in C57Bl/6 mice expressed the sigma-2 receptor at significantly higher levels than normal mouse tissues, and the selective accumulation of the sigma-2 receptor ligand in the tumor could be used to image the tumor in vivo. These findings suggest that sigma-2 receptor ligands have potential utility for diagnostic imaging of pancreatic cancer extending the spectrum of their utility beyond what has previously been reported for breast cancer and supporting the hypothesis that the sigma-2 receptor is a generic marker for cellular proliferation [18, 29–31].
Targeting the sigma-2 receptor may also have utility in cancer treatment. Ligands to the sigma-2 receptor (WC26, SV119, and haloperidol) caused dose-dependent apoptosis in all tumor cell lines in vitro, while the sigma-1 receptor-selective ligand pentazocine did not cause cell death in three of four pancreatic cancer cell lines. Interestingly the CFPAC cell line underwent dose dependent cell death in the pentazocine treatment group. Sigma-1 antagonists have been shown to induce apoptosis, suggesting that CFPAC cells may have a different defect in their apoptotic program.
The mechanism of sigma-2 receptor ligand-induced cell death has not been established. Previous studies have reported that sigma 2 receptor-specific ligands induce apoptosis in a p53- and caspase-independent manner by causing oxidative stress and increasing the concentration of intracellular ceramide [33, 34]. Other groups have shown that the caspase-dependent mitochondrial pathway is activated in response to treatment with sigma 2 receptor-specific ligands . Our results show that inhibition of the executioner caspases abrogates WC26-induced apoptosis in pancreas adenocarcinoma cell lines, suggesting that sigma 2 receptor-specific ligand-induced apoptosis may be cell type and/or ligand specific. Pancreas cancer cells incubated with sigma-2 receptor ligands were found to have active caspase-3 within 4–6 hours and DNA fragmentation within 20 hours (data not shown). Furthermore, pan-caspase and caspase-3/7 specific inhibition rescued sigma-2 receptor ligand-treated cells from death. Our data do not clarify whether sigma-2 receptor-specific ligand-induced cell death occurs predominantly by the mitochondrial (intrinsic) or receptor-mediated pathway (extrinsic).
Our results are consistent with previous reports describing cancer cell-selectivity of sigma-2 receptor ligands as well as the ability of these molecules to cause caspase-dependent cell death (apoptosis) both in vitro and in vivo. By establishing that pancreas cancer cell lines and Panc-02 tumor allografts established in C57Bl/6 mice respond similarly to sigma-2 receptor ligands, we have extended the utility of these molecules and are demonstrating the generality of targeting the sigma-2 receptor for both diagnostic and therapeutic applications. Importantly, we showed that 24 hours after a single dose of WC26 there was significant tumor apoptosis in vivo with minimal apoptosis in normal tissues. More apoptosis was observed in Panc-02 cells grown in vivo than in the same cell line grown in vitro. This result is likely due to the up to 20-fold difference in concentrations of the sigma 2 receptor-specific ligand between these experiments, but could also be due to differential sensitivity of the Panc-02 cells when grown in 2-dimensional culture compared to the 3-dimensional architecture adopted in vivo. Although a small amount of caspase-3 activity was seen in normal liver and pancreas in dissociated tissues, this finding was not recapitulated in an immunohistochemical study of normal tissues after WC26 treatment (data not shown). Furthermore, there were no apparent, systemic side effects in the WC26 treated animals (Figure 5B).
In addition to causing tumor cell apoptosis in vivo with minimal peripheral toxicity, sigma-2 receptor ligand treatment of tumor-bearing mice led to tumor stability and regression in some animals. Although all tumors regrew shortly after treatment was stopped, WC26-treated tumors remained smaller and fewer ulcerated than tumors in vehicle-injected control animals. Systemic therapy with WC26 was successful in reducing tumor mass and/or altering the course of tumor growth after therapy. If patients with locally advanced pancreatic cancer respond similarly to treatment with sigma-2 receptor ligands they might become candidates for pancreatic cancer treatment.
Using small molecule probes we have demonstrated that the sigma-2 receptor is selectively over-expressed on pancreas cancer cells both in vitro and in vivo. We have also shown proof of principle that this finding can be exploited for both diagnostic imaging and therapeutic use. We have identified the sigma-2 receptor as a potential target for the treatment of pancreas cancer; selectively triggering or sensitizing tumor cells toward apoptosis.
Materials and methods
Sigma receptor compounds and chemicals
Sigma-1 and sigma-2 receptor ligands (Figure 1) were synthesized as previously described . Caspase inhibitors (ZVAD-FMK, YVAD-CHO, and DEVD-CHO) were obtained from Calbiochem (San Diego, CA). Unless otherwise specified, all other materials were obtained from Sigma-Aldrich (Saint Louis, Missouri, USA).
Mouse pancreatic cancer (Panc-02) and several human pancreatic cell lines (CFPAC-1, AsPC-1, and Panc-1) were maintained in supplemented RPMI containing glutamine (2 mmol/L), pyruvate (1 mmol/L), penicillin and streptomycin (100 IU/mL), and 10% FBS. All cell culture processes were carried out in a humidified atmosphere of 5% CO2 at 37°C.
Sigma-2 expression study in vitro
Lung, liver, spleen, kidney, pancreas, brain and established tumor from C57BL/6 mice were minced to 1-mm in size and digested in a RPMI buffer containing 1 mg/ml collagenase (Sigma-Aldrich, St. Louis, MO) and 0.1 mg/ml DNase (Sigma-Aldrich, St. Louis, MO) for 45 min to obtain a single-cell suspensions. After filtering, contaminating erythrocytes were lysed in Ammonium Chloride (ACK) buffer, pelleted and resuspended in PBS (pH 7.4). Single cell suspensions were incubated for 1 hour with KO5-138 (a fluorescent labeled sigma-2 receptor ligand, Figure 1) at 50 nM or 100 nM of ligand, left unstained. All lines were then washed 3 times with PBS, and evaluated by Fluorescence Activated Cell Sorting (FACS).
Binding assays (Scatchard analysis)
The tritiated compound [3H]RHM-1 was synthesized by American Radiolabeled Chemicals, Inc. (St. Louis, MO) via O-alkylation of the corresponding phenol precursor as previously described; chemical purity was greater than 99% and the specific activity of the radioligand was 80 Ci/mmol. Membrane homogenates were prepared from ~400 mg Panc-02 mouse tumor allografts, which were removed from tumor bearing mice and frozen on dry ice immediately and stored at -80°C until used. Before homogenization, the tumor allografts were allowed to thaw slowly on ice. Tissue homogenization was carried out at 4°C using a Potter-Elvehjem tissue grinder at a concentration of 1 g of tissue/ml of 50 mM Tris-HCl at pH 8.0. The crude membrane homogenate was then transferred to a 50 ml centrifuge tube and resuspended to a concentration of 200 mg of tissue/ml of 50 mM Tris-HCl. Additional homogenization was accomplished using an Ultra-Turrax T8 polython homogenizer (IKA Works, Inc, Wilmington, NC). The final homogenate was then centrifuged for 10 min at 1000 g, the pellet discarded and the supernatant mixed by vortexing and stored at -80°C until used. The protein concentration of the suspension was determined (DC protein assay, Bio-Rad, Hercules, CA) and averaged ~10 mg of protein/ml of stock solution. Approximately 200 μg membrane homogenates were diluted with 50 mM Tris-HCl buffer, pH 8.0 and incubated with [3H]RHM-1 in a total volume of 150 μl at 25°C in 96 well polypropylene plates (Fisher Scientific, Pittsburgh, PA). The concentrations of the radioligand ranged from 0.1–18 nM. After incubation of 60 min, the reactions were terminated by the addition of 150 μl of cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4, at 4°C) using a 96 channel transfer pipette (Fisher Scientific, Pittsburgh, PA), and the samples harvested and filtered rapidly to 96 well fiber glass filter plate (Millipore, Billerica, MA) that had been presoaked with 100 μl of 50 mM Tris-HCl buffer, pH 8.0 for 1 hour. Each filter was washed with 200 μl of ice-cold wash buffer for a total of three washes. A Wallac 1450 MicroBeta liquid scintillation counter (Perkin Elmer, Boston, MA) was used to quantitate the bound radioactivity, non-specific binding was determined from samples which contained 10 μM RHM-1. The equilibrium dissociation constant (Kd) and maximum number of binding sites (Bmax) were determined by a linear regression analysis of the transformed data using the method of Scatchard.
Bs is the amount of the radioligand bound specifically; L is the concentration of radioligand. nH, Hill slope, was determined from Hill plot of versus logL.
Sigma-2 expression study in vivo
MicroPET (positron emission tomography)/CT Imaging was performed to confirm the uptake of the sigma-2 receptor ligand after injection of [18F]4 labeled Sigma-2 ligand; RHM-4 in tumor bearing mice. Briefly, female C57Bl/6 mice were implanted subcutaneously in the nape of the neck with Panc-02 mouse pancreatic adenocarcinoma cells (1.0 × 106 cells in 200 μl RPMI) 7–10 days before the study date. Average tumor burden on the day of imaging was ~1.0 cm3. The animals were injected with of [18F]4 labeled Sigma-2 ligand via tail vein and imaged at 2 hours after injection.
Evaluation of cytotoxicity of sigma-2 ligands in vitro
Tumor cells were seeded at a density of approximately 0.2 × 106 cells per well in 12-well plates in 1.0 ml culture medium. Cells were split and pre-incubated at 37°C in humidified 5% CO2 for more than 24 hours (Panc-02) and 48 hours (CFPAC-1, AsPC-1, Panc-1) to insure uniform growth conditions. Compounds were dissolved in DMSO and added to the culture medium at the concentrations indicated. The final concentration of DMSO in the cell culture medium was less than 1%. The cells were then incubated for 24 hours at 37°C in humidified 5% CO2. The extent of apoptosis was subsequently measured as previously reported. Briefly, staining was performed on trypsin-EDTA treated cultures that had been fixed with 1% paraformaldehyde and 90% methanol. Cell pellets were resuspended in TUNEL reagent (APO-BRDU kit, San Diego, CA) or cleaved caspase-3 antibody (Cell Signaling Technology, Inc. Boston, MA) and incubated overnight at room temperature (TUNEL) or 4°C (cleaved caspase-3). After washing, cells were resuspended in fluorescein antibody or 7-AAD buffer and incubated for 1 hour at room temperature. Cell-associated fluorescence was determined using a flow cytometry (FACScan, BD Biosciences) and analyzed with CellQuest software (BD Biosciences).
Antitumor effect of sigma-2 receptor ligand in vivo
All studies were performed in accordance with an animal protocol approved by the Washington University Institutional Animal Care Facility. Female C57BL/6 mice (8–12 weeks old) were purchased from the NCI and acclimated for at least 1 week before tumor implantation. All mice were injected in the right flank with 200 μl of a single cell suspension containing 1.0 × 106 Panc-02 cells. Treatment of the tumors started 2 weeks after tumor implantation when their size reached a mean diameter of 5–8 mm. To evaluate the effect of sigma-2 receptor ligands both systemically and on tumor in vivo, several mice were sacrificed after a single treatment. Necropsy was performed and single cell suspensions were prepared from retrieved organs. The extent of apoptosis in these cells was measured by FACS (described above). For the survival study, mice (N = 10 per group) were treated with sigma-2 receptor ligand at the stated concentration or vehicle control once a day for 5 days. Mean tumor diameter was measured three times each week. All mice were euthanized when the tumors reached a mean diameter of 15 mm or when the tumors ulcerated .
For in vivo experiments, Kaplan-Meier survival curves were plotted and differences were compared using a log-rank test. Tumor sizes and FACS results were analyzed using linear mixed repeated measures models. Hypothesis tests were corrected for multiple testing using a Hochberg step-up procedure. A p-value of less than 0.05 was considered significant for all analyses.
This work was supported in part by a Barnes Jewish Hospital Foundation Grant (WGH), AACR-PanCAN Career Development Award in Pancreatic Cancer Research, in Memory of Skip Viragh (WGH), GM055194 (RSH), GM044118 (RSH) and DDRCC 5P30 DK052574. Portions of this work were presented at the Annual Meeting of the Society for Surgical Oncology Cancer Forum, Washington, DC 2007, and American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, Florida 2007.
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66.View ArticlePubMedGoogle Scholar
- Prochazkova J, Lichnovsky V, Kylarova D, Erdosova B, Vranka P: Involvement of p53 and Bcl-2 family proteins in regulating programmed cell death and proliferation in human embryogenesis. Gen Physiol Biophys. 2004, 23: 209-229.PubMedGoogle Scholar
- Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell. 2004, 116: 205-219. 10.1016/S0092-8674(04)00046-7View ArticlePubMedGoogle Scholar
- Debatin KM, Krammer PH: Death receptors in chemotherapy and cancer. Oncogene. 2004, 23: 2950-2966. 10.1038/sj.onc.1207558View ArticlePubMedGoogle Scholar
- Bergman PJ, Harris D: Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract. 1997, 27: 47-57.View ArticlePubMedGoogle Scholar
- Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E: Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell. 2005, 7: 227-238. 10.1016/j.ccr.2005.02.008View ArticlePubMedGoogle Scholar
- Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M: TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene. 2004, 23: 1153-1165. 10.1038/sj.onc.1207224View ArticlePubMedGoogle Scholar
- Ryu J, Lee HJ, Kim KA, Lee JY, Lee KS, Park J, Choi SY: Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol Cells. 2004, 17: 353-359.PubMedGoogle Scholar
- Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG: TAT-Bim Induces Extensive Apoptosis in Cancer Cells. Ann Surg Oncol. 2007, 14: 1763-1771. 10.1245/s10434-006-9298-zView ArticlePubMedGoogle Scholar
- Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999, 285: 1569-1572. 10.1126/science.285.5433.1569View ArticlePubMedGoogle Scholar
- Leibel SA, Fuks Z, Zelefsky MJ, Hunt M, Burman CM, Mageras GS, Chui CS, Jackson A, Amols HI, Ling CC: Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol. 2003, 30: 596-615. 10.1016/S0093-7754(03)00354-3View ArticlePubMedGoogle Scholar
- Kumar PS, Pegram M: Targeting HER2 Epitopes. Semin Oncol. 2006, 33: 386-391. 10.1053/j.seminoncol.2006.04.004View ArticleGoogle Scholar
- Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Emmanouilides C, Doufexis D, Sahanas S, Kontopidou FN, Kalpadakis C, Angelopoulou MK, Dimitriadou EM, Kokoris SI, Panayiotidis P: Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem. 2006, 6: 1657-1686. 10.2174/156802606778194235View ArticlePubMedGoogle Scholar
- MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM: Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 2005, 12: 773-782. 10.1038/sj.cdd.4401649View ArticlePubMedGoogle Scholar
- Kline T, Torgov MY, Mendelsohn BA, Cerveny CG, Senter PD: Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharm. 2004, 1: 9-22. 10.1021/mp0340183View ArticlePubMedGoogle Scholar
- Ippolito JE, Merritt ME, Backhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI: Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc Natl Acad Sci U S A. 2006, 103: 12505-12510. 10.1073/pnas.0605207103PubMed CentralView ArticlePubMedGoogle Scholar
- Nakajima M, Toga W: Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor. Nippon Yakurigaku Zasshi. 2003, 122: 482-490.View ArticlePubMedGoogle Scholar
- Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH: Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer. 2000, 82: 1223-1232. 10.1054/bjoc.1999.1067PubMed CentralView ArticlePubMedGoogle Scholar
- Crawford KW, Bowen WD: Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62: 313-322.PubMedGoogle Scholar
- Barg J, Thomas GE, Bem WT, Parnes MD, Ho AM, Belcheva MM, McHale RJ, McLachlan JA, Tolman KC, Johnson FE, : In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells. J Neurochem. 1994, 63: 570-574.View ArticlePubMedGoogle Scholar
- Colabufo NA, Berardi F, Contino M, Ferorelli S, Niso M, Perrone R, Pagliarulo A, Saponaro P, Pagliarulo V: Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett. 2006, 237: 83-88. 10.1016/j.canlet.2005.05.027View ArticlePubMedGoogle Scholar
- Brent PJ, Pang GT: Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol. 1995, 278: 151-160. 10.1016/0014-2999(95)00115-2View ArticlePubMedGoogle Scholar
- Zhou X, Hansson GK: Effect of sex and age on serum biochemical reference ranges in C57BL/6J mice. Comp Med. 2004, 54: 176-178.PubMedGoogle Scholar
- Shi X, Liu S, Kleeff J, Friess H, Buchler MW: Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002, 62: 354-362. 10.1159/000065068View ArticlePubMedGoogle Scholar
- Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60: 5451-5455.PubMedGoogle Scholar
- Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA: Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003, 9: 33-41.View ArticlePubMedGoogle Scholar
- Catz SD, Johnson JL: BCL-2 in prostate cancer: a minireview. Apoptosis. 2003, 8: 29-37. 10.1023/A:1021692801278View ArticlePubMedGoogle Scholar
- Daniel JC, Smythe WR: The role of Bcl-2 family members in non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2004, 16: 19-27. 10.1053/j.semtcvs.2004.01.002View ArticlePubMedGoogle Scholar
- Kassiou M, Dannals RF, Liu X, Wong DF, Ravert HT, Scheffel UA: Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorg Med Chem. 2005, 13: 3623-3626. 10.1016/j.bmc.2005.03.039View ArticlePubMedGoogle Scholar
- Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH: [3H]N-[4-(3, 4-dihydro-6, 7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5 -methylbenzamide: a novel sigma-2 receptor probe. Eur J Pharmacol. 2005, 525: 8-17. 10.1016/j.ejphar.2005.09.063View ArticlePubMedGoogle Scholar
- Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT: Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997, 57: 156-161.PubMedGoogle Scholar
- Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S: Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004, 64: 4875-4886. 10.1158/0008-5472.CAN-03-3180View ArticlePubMedGoogle Scholar
- Crawford KW, Coop A, Bowen WD: sigma(2) Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol. 2002, 443: 207-209. 10.1016/S0014-2999(02)01581-9View ArticlePubMedGoogle Scholar
- Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M: Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005, 65: 8975-8983. 10.1158/0008-5472.CAN-05-0269View ArticlePubMedGoogle Scholar
- Wei Z, Mousseau DD, Dai Y, Cao X, Li XM: Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. Pharmacogenomics J. 2006, 6: 279-288.PubMedGoogle Scholar
- Vangveravong S, Xu J, Zeng C, Mach RH: Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg Med Chem. 2006, 14: 6988-6997. 10.1016/j.bmc.2006.06.028View ArticlePubMedGoogle Scholar
- Tu Z, Dence CS, Ponde DE, Jones L, Wheeler KT, Welch MJ, Mach RH: Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer. Nucl Med Biol. 2005, 32: 423-430. 10.1016/j.nucmedbio.2005.03.008View ArticlePubMedGoogle Scholar
- Scatchard G: The attractions of proteins for small molecules and ions. Ann N Y Acad Sci. 1949, 51: 660-672. 10.1111/j.1749-6632.1949.tb27297.x.View ArticleGoogle Scholar
- Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN: Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res. 2002, 102: 137-143. 10.1006/jsre.2001.6302View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.